The aim of this study is to search the prognostic value of SPARC expression in rectum cancer cases receiving postoperative radiotherapy.
METHODS:
Forty three rectal cancer patients are recruited to this retrospective study. All patients received postoperative radiotherapy which the median dose was 5040 cGy and concomitant chemotherapy. Samples taken from their paraffin blocks were examined with immunohistochemical procedures.
RESULTS:
When the association between SPARC expression and the clinicopathological feature was examined, there was a significant association between age and expression levels. Overall survival of patients with low expression was found to be 67 months whereas the overall survival of the patients with high expression was 32 months and the difference was statistically significant. Time to local recurrence of patients with low expression was found to be 74 months whereas time to local recurrence of the patients with high expression was 31 months. Progression free survival of the patients with low expression and high expression were 67 months and 32 months, respectively. In multivariate Cox regression analyses, high expression of SPARC was found to be associated with a statistically significant shorter overall survival and progression free survival.
CONCLUSIONS:
High expression of SPARC is related to worse prognosis in rectal cancer patients.
ArnoldS.A., RiveraL.B., CarbonJ.G., et al., Losartan Slows Pancreatic Tumor Progression and Extends Survival of Sparc-Null Mice by Abrogating Aberrant Tgfβ Activation, PLoS One,7 (2012), e31384.
2.
BhoopathiP., ChettyC., DontulaR., et al., Sparc Stimulates Neuronal Differentiation of Medulloblastoma Cells Via the Notch1/Stat3 Pathway, Cancer Research,71 (2011), 4908-19.
3.
CheethamS., TangM., MesakF., KenneckeH., OwenD. and TaiI., Sparc Promoter Hypermethylation in Colorectal Cancers Can Be Reversed by 5-Aza-2' Deoxycytidine to Increase Sparc Expression and Improve Therapy Response, British Journal of Cancer,98 (2008), 1810-19.
4.
ChettyC., DontulaR., GujratiM., DinhD.H. and LakkaS.S., Blockade of Sox4 Mediated DNA Repair by Sparc Enhances Radioresponse in Medulloblastoma, Cancer Letters,323 (2012), 188-98.
5.
ChewA., SalamaP., RobbshawA., et al., Sparc, Foxp3, Cd8 and Cd45 Correlation with Disease Recurrence and Long-Term Disease-Free Survival in Colorectal Cancer, PLoS One,6 (2011), e22047.
6.
1, 'Modulation of Matrix Remodeling by Sparc in Neoplastic Progression', in Seminars in cell & developmental biology (Elsevier, 2010), pp. 55-65.
7.
DesaiN.P., TrieuV., HwangL.Y., WuR., Soon-ShiongP. and GradisharW.J., Improved Effectiveness of Nanoparticle Albumin-Bound (Nab) Paclitaxel Versus Polysorbate-Based Docetaxel in Multiple Xenografts as a Function of Her2 and Sparc Status, Anti-Cancer Drugs,19 (2008), 899-909.
8.
FenouilleN., RobertG., TichetM., et al., The P53/P21cip1/ Waf1 Pathway Mediates the Effects of Sparc on Melanoma Cell Cycle Progression, Pigment Cell & Melanoma Research,24 (2011), 219-32.
9.
HanW., CaoF., ChenM.-B., et al., Prognostic Value of Sparc in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis, PloS one,11 (2016), e0145803.
10.
HeitzerE., ArtlM., FilipitsM., et al., Differential Survival Trends of Stage Ii Colorectal Cancer Patients Relate to Promoter Methylation Status of Pcdh10, Sparc, and Uchl1, Modern Pathology,27 (2014), 906-15.
11.
IzmirliM., AlptekinD. and KilicU., Epigenetic Modifications in Urooncology, Handbook of Genitourinary Medicine, 143.
12.
KaladyM.F., DejuliusK.L., SanchezJ.A., et al., Braf Mutations in Colorectal Cancer Are Associated with Distinct Clinical Characteristics and Worse Prognosis, Diseases of the Colon & Rectum,55 (2012), 128-33.
13.
KimJ.Y., JeongD., AhnT.S., et al., Expression of Secreted Protein Acidic and Rich in Cysteine in the Stroma of a Colorectal Carcinoma Is Associated with Patient Prognosis, Annals of Coloproctology,29 (2013), 93-99.
14.
KurtulN., ErogluC., UnalD., et al., Prognostic Value of Sparc Expression in Unresectable Nsclc Treated with Concurrent Chemoradiotherapy, Asian Pac J Cancer Prev,15 (2014), 8911-6.
15.
LiangJ.-F., WangH.-K., XiaoH., et al., Relationship and Prognostic Significance of Sparc and Vegf Protein Expression in Colon Cancer, Journal of Experimental & Clinical Cancer Research,29 (2010), 1.
16.
LienH., HsiaoY., LinY., et al., Molecular Signatures of Metaplastic Carcinoma of the Breast by Large-Scale Transcriptional Profiling: Identification of Genes Potentially Related to Epithelial-Mesenchymal Transition, Oncogene,26 (2007), 7859-71.
17.
LièvreA., BachetJ.-B., BoigeV., et al., Kras Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab, Journal of Clinical Oncology,26 (2008), 374-79.
18.
LinharesM.M., Affonso JrR.J., De Souza VianaL., et al., Genetic and Immunohistochemical Expression of Integrins Itgav, Itga6, and Itga3 as Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival, PloS One,10 (2015), e0144333.
19.
LiuQ., GaoX., ChangW., et al., Secreted Protein Acidic and Rich in Cysteine Expression in Human Colorectal Cancer Predicts Postoperative Prognosis, Eur Rev Med Pharmacol Sci,19 (2015), 1803-11.
20.
NagarajuG.P. and Ei-RayesB.F., Sparc and DNA Methylation: Possible Diagnostic and Therapeutic Implications in Gastrointestinal Cancers, Cancer Letters,328 (2013), 10-17.
21.
OnozM., BasaranR., GucluerB., et al., Correlation between Sparc (Osteonectin) Expression with Immunophenotypical and Invasion Characteristics of Pituitary Adenomas, APMIS,123 (2015), 199-204.
22.
PodhajcerO.L., BenedettiL.G., GirottiM.R., PradaF., SalvatierraE. and LleraA.S., The Role of the Matricellular Protein Sparc in the Dynamic Interaction between the Tumor and the Host, Cancer and Metastasis Reviews,27 (2008), 691-705.
23.
RobertG., GaggioliC., BailetO., et al., Sparc Represses E-Cadherin and Induces Mesenchymal Transition During Melanoma Development, Cancer Research,66 (2006), 7516-23.
24.
SoreideK., BergM., SkudalB.S. and NedreboeB.S., Advances in the Understanding and Treatment of Colorectal Cancer, Discovery Medicine,12 (2011), 393-404.
25.
SosaM.S., GirottiM.R., SalvatierraE., et al., Proteomic Analysis Identified N-Cadherin, Clusterin, and Hsp27 as Mediators of Sparc (Secreted Protein, Acidic and Rich in Cysteines) Activity in Melanoma Cells, Proteomics,7 (2007), 4123-34.
26.
TaiI.T. and TangM.J., Sparc in Cancer Biology: Its Role in Cancer Progression and Potential for Therapy, Drug Resistance Updates,11 (2008), 231-46.
27.
TutT.G., LimS.H., DissanayakeI.U., et al., Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer, PLoS One,10 (2015), e0129313.
28.
VannahmeC., G"oslingS., PaulssonM., MaurerP. and HartmannU., Characterization of Smoc-2, a Modular Extracellular Calcium-Binding Protein, Biochemical Journal,373 (2003), 805-14.
29.
YangE., KangH.J., KohK.H., RheeH., KimN.K. and KimH., Frequent Inactivation of Sparc by Promoter Hypermethylation in Colon Cancers, International Journal of Cancer,121 (2007), 567-75.
30.
YoshimuraT., NagaharaM., KuoC., TurnerR.R., Soon-ShiongP. and HoonD.S., Lymphovascular Invasion of Colorectal Cancer Is Correlated to Sparc Expression in the Tumor Stromal Microenvironment, Epigenetics,6 (2011), 1001-11.
31.
ZhouY., HofstetterW.L., HeY., et al., Klf4 Inhibition of Lung Cancer Cell Invasion by Suppression of Sparc Expression, Cancer Biology & Therapy,9 (2010), 507-13.
